JavaScript is disabled. Please enable to continue!

Mobile search icon
Eurofins >> BioPharma Services >> CDMO >> Services >> Orphan Drugs

Orphan Drugs

Sidebar Image

Orphan Drugs Specifications

In Europe rare diseases are those affecting less than 1 in 2,000 people and in the USA, fewer than 200,000 people. These diseases are mostly genetic in origin affecting young children and inevitably require long term, lifelong treatment.

Today around 30 million people live with rare and severe diseases in EU and USA and there are more than 7,000 rare and severe diseases known while only around 400 specific orphan drugs are available on the market to treat rare diseases.

In this context, Orphan drugs have become a public health priority in USA, EU and JP supported by various incentives (accelerated regulatory review, market exclusivity, reduced application fees...)

Our Expertise

As a very experienced CDMO with fully scalable GMP manufacturing facilities Eurofins CDMO network of companies is ideally suited for the development of Orphan medicinal products:
Our Experience
  • Several Orphan medicinal products manufactured for commercial use in EU and JP markets
  • More than 25 development and clinical batches produced for rare diseases

 

Contact your CDMO expert >